CureVac signals progress on mRNA flu vaccine
CureVac NV (CVAC) said Tuesday that it has selected an mRNA flu vaccine candidate for continued clinical development, based on positive results from an early-stage study conducted in collaboration with GSK PLC (GSK.LN). The investigational vaccine provides broad antigen coverage against flu strains recommended by the World Health Organization and will advance to a phase 2 study, with dosing of the first study participant expected in the fourth quarter of this year, the company said in a release. The mRNA technology platform's speed and flexibility "offers tremendous potential to overcome the current challenges associated with providing seasonally updated and highly effective influenza vaccines," Dr. Myriam Mendila, CureVac's chief development officer, said in a statement. CureVac shares gained 1.5% premarket on Tuesday and are up more than 40% in the year to date, while the S&P 500 has gained 16.9%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
09-12-23 0805ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks